The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A

2002 ◽  
Vol 12 (3) ◽  
pp. 174-178 ◽  
Author(s):  
V. Tugnoli ◽  
R. Marchese Ragona ◽  
R. Eleopra ◽  
R. Quatrale ◽  
J. G. Capone ◽  
...  
2001 ◽  
Vol 24 (6) ◽  
pp. 297-302 ◽  
Author(s):  
S. Rodopoulou ◽  
E. Keramidas ◽  
N. Metaxotos ◽  
G. Tagaris ◽  
E. Tsati ◽  
...  

2015 ◽  
Vol 4 (11) ◽  
pp. 1639-1650 ◽  
Author(s):  
Shang Xie ◽  
Kan Wang ◽  
Tao Xu ◽  
Xue‐Sheng Guo ◽  
Xiao‐Feng Shan ◽  
...  

2017 ◽  
Vol 92 (6) ◽  
pp. 891-892
Author(s):  
Gustavo Vieira Gualberto ◽  
Felipe Mauricio Soeiro Sampaio ◽  
Natália Augusta Brito Madureira

1998 ◽  
Vol 107 (1) ◽  
pp. 52-55 ◽  
Author(s):  
Ollivier Laccourreye ◽  
Luca Muscatelo ◽  
Carole Naude ◽  
Brigitte Bonan ◽  
Daniel Brasnu

Fourteen patients with severe Frey's syndrome (occurring after conservative parotidectomy) managed with intracutaneous injection of botulinum toxin type A were prospectively evaluated. Results were analyzed for effectiveness, complications, and adverse effects. Complications were not encountered. The only adverse effect noted was a temporary and slight partial paresis of the upper lip of 3 months' duration in 2 patients. Permanent paresis was not encountered. Frey's syndrome was always controlled within 2 days following the intracutaneous injection of botulinum toxin A. Frey's syndrome recurrence was not encountered with a follow-up duration that varied from 3 to 9 months (mean follow-up 7 months). This preliminary report confirmed that in patients who have Frey's syndrome after conservative parotidectomy, the intracutaneous injection of botulinum toxin is a valuable treatment option that should be further investigated.


2005 ◽  
Vol 161 (12) ◽  
pp. 1245
Author(s):  
M.S. El-Tamawy ◽  
A. Abdel-Kader ◽  
F. Shereen ◽  
S. Hatem ◽  
N. Abo-Krysha ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Gaurav Verma

Trigeminal neuralgia (TN) is a clinical condition characterized by paroxysmal attacks of severe and electric shock-like pain along the distribution of one or more branches of the trigeminal nerve. Various medicinal or surgical modalities have been employed in the past with variable success. Newer methods were tried in search of permanent cure or long-lasting pain relief. The purpose of this paper is to present the review of the literature regarding the use of botulinum toxin type-A (BTX-A) in the management of trigeminal neuralgia.


Sign in / Sign up

Export Citation Format

Share Document